CN1239657A - Antisticking particle and powder containing sodium hyaluronate and their preparation process - Google Patents
Antisticking particle and powder containing sodium hyaluronate and their preparation process Download PDFInfo
- Publication number
- CN1239657A CN1239657A CN 98110311 CN98110311A CN1239657A CN 1239657 A CN1239657 A CN 1239657A CN 98110311 CN98110311 CN 98110311 CN 98110311 A CN98110311 A CN 98110311A CN 1239657 A CN1239657 A CN 1239657A
- Authority
- CN
- China
- Prior art keywords
- granule
- powder spray
- antisticking
- prescription
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention relates to medicine. Of the antisticking particle and powder, the main component is sodium hyaluronate, which is also named as sodium hyaluronate and may be also compounded into compounded preparation with other separating agent and pharmacological active matters, such as anticoagulant, antiphlogistic, calcium passage retarder, cytostatic agent and proteolytic enzyme. The antisticking particle and powder of the present invention consists of sodium hyaluronate 1-100 wt%, separating agent 0-99 wt% and active component in the amound based on relevant pharmacopeia. The antisticking particle and powder of the present invention is used for antisticking after operation in abdominal cavity, gynaecological and obstetrical operation, orthopedical operation and thoracic operation and has excellent antisticking effect.
Description
The invention belongs to field of pharmaceutical technology, is granule and the powder spray of tissue adhesion behind a kind of prevention and the treatment surgical operation.Adhesion often betides after abdominal cavity, gynecological, orthopaedics, cardiothoracic surgery and the orthopaedic surgery, can cause serious clinical complication, as intestinal obstruction, abdominal cavity and pelvic cavity pain, infertility etc., increased the difficulty of operation once more, and further complication may take place.Film with Preventing Adhesion is mainly by two approach at present: improve operation skill and use adjuvant.Improve operation skill and comprise directly operation of minimizing, reduce the wound in the operation process and avoid the interior foreign body that imports of body.Play the effect that reduces adhesion to a certain extent by improving operation skill, but because its limitation can not effectively prevent adhesion.Adjuvant divides medicine and interleaving agent again, once medicine of using such as hyaluronidase, streptokinase, urokinase, ibuprofen, dexamethasone etc. in the past, and interleaving agent such as dextran, polyvinylpyrrolidone (PVP), sodium carboxymethyl cellulose (CMC) etc., though obtain certain effect, do not have a kind of method of determined curative effect to prevent the postoperative tissue adhesion yet.The special hydrodynamic characteristics of hyaluronate sodium (English Sodium Hyaluronate claims hyaluronic acid sodium again) makes it have height viscoelasticity, plasticity, permeability and good biocompatibility.Use hyaluronate sodium to prevent the postoperative tissue adhesion, the incidence rate of adhesion is reduced greatly.Zoopery both domestic and external and clinical data proof hyaluronate sodium are effective anti-blocking agents.
A kind of linear polyanionic polysaccharide that hyaluronate sodium is made up of the disaccharidase recurring unit of (1 → 3)-2-acetylaminohydroxyphenylarsonic acid 2-deoxidation-β-D-glucose-(1 → 4)-O-D-glucuronic acid.As the necessary material of Human Physiology, it extensively is present in the various tissues of animal, comprises connective tissue, skin, cartilage, vitreum and synovial fluid etc.Hyaluronate sodium and tissue fibrin have viscoelasticity, protectiveness, lubricity and stable substrate in conjunction with formation, and cell is inlayed wherein, the effect that has tytosis space, stabilized cell structure, covers cell and protection cell.The hyaluronate sodium molecular weight can reach 400 ten thousand to 5 megadaltons, in aqueous solution, exists with random spiral form, and very big molecule volume is arranged, and (＜0.01%) can be woven and penetrate mutually under low concentration, makes it have specific rheological properties.Hyaluronate sodium prevents postoperative tissue adhesion's mechanism to reduce 1., and the dissolving back forms the polymolecular network structure, and wounded tissue is separated with normal serous coat, plays space obstacle effect and lubrication, reduces friction; 2. suppress hemorrhage and ooze out, reduce the clot quantity that can form permanent adhesion skeleton, the Profilin calmness; 3. suppress post-operation inflammatory cell migration and phagocytosis, suppress hematoblastic deposition, promote wound healing; 4. stimulate the growth and the differentiation of serous coat cell, make the wound serous coat reach the physiological reparation.In addition, hyaluronic acid sodium granules and powder spray are preventing to be better than sodium hyaluronate solution and gel aspect the tissue adhesion.Sodium hyaluronate solution and gel are because concentration is low, molecular weight is little, be absorbed degraded in vivo soon, weakened its iris action, and hyaluronic acid sodium granules and powder spray spray behind tissue surface, a course of dissolution is progressively arranged at tissue surface, form the high concentration gel simultaneously in the part, retention time is long in local viscoelasticity height and the body, forms effective barrier in the serous coat reparation phase, so its preventing adhesiving effect is remarkable.Hyaluronic acid sodium granules and powder spray steady quality, using method is easy, meets the requirement of clinical use.
The chemical property of hyaluronate sodium is stable, does not produce physical and chemical reaction with the most drug compatibility, and it can use existing many example proofs with compatibilities such as many anticoagulant, hormone, anti-inflammatory analgesics.
Purpose of the present invention: tissue adhesion's granule and powder spray after providing a kind of prevention and treating surgical operation, also can same anticoagulant, antiinflammatory, proteolytic enzyme, calcium channel blocker, cytostatic agent and interleaving agent are made into compound preparation, constituting a series of is the anti-blocking agent of carrier with the hyaluronate sodium, be used for abdominal surgery, department of obstetrics and gynecology, operation such as cardiothoracic surgery back prevention peritoneal tissues or pericardium adhesion, also can be used for preventing arthroscopy, around the nervous tissue, tissue adhesion behind the bone surgeries such as tendon repair, it is long to have the interior retention time of body, preventing adhesiving effect significantly and significantly reduce the effect of post-operative complication, the promotion wound healing is arranged simultaneously, reduce the advantage of cicatrix; And provide the preparation method of this class granule and powder spray.
The basic comprising of granule of the present invention and powder spray is: hyaluronate sodium, or hyaluronate sodium and dextran, or hyaluronate sodium and polyvinylpyrrolidone (PVP), or hyaluronic acid and carboxymethyl cellulose.Tissue adhesion after being used for prevention and treating surgical operation reduces post-operative complication
Also can on the basis of basic comprising, add pharmacological active substance, as required as anticoagulant, antiinflammatory, calcium channel blocker, cytostatic agent, proteolytic enzyme and other interleaving agent.Anticoagulant such as dicoumarol, heparin, hirudin etc., antihistaminics such as antiinflammatory such as promethazine, hormones such as dexamethasone, hydrocortisone, andrographolide, NSAID (non-steroidal anti-inflammatory drug) such as ibuprofen, oxyphenbutazone, tolmetin; Calcium channel blocker example hydrochloric acid diltiazem, nifedipine, verapamil hydrochloride; Cytostatic agent such as fluorouracil; Protein hydrolytic reagent such as hyaluronidase, streptokinase, urokinase, pepsin, trypsin, cytoplastin, plasminogen (tPA), interleaving agent such as agar, albumin, Oleum Camphora, chondroitin sulfate, fat, Radix Acaciae senegalis, olive oil, paraffin, phospholipid, polysiloxanes, vaseline, gelatin, oxidized regenerated cellulose, expanded polytetrafluoroethylsealing etc.
The prescription and the amount ranges of granule of the present invention and powder spray are: in 100 gram granule and powder sprays, and hyaluronate sodium 1-100 gram wherein, in the time of need be with interleaving agent, its amount ranges 0-99 gram, in the time of need adding medicine, its consumption is according to the pharmacopeia pertinent regulations
The prescription and the consumption of granule of the present invention and powder spray are: in 100 gram granule and powder sprays, and hyaluronate sodium 100 grams
The prescription and the consumption of granule of the present invention and powder spray are: in 100 gram granule and powder sprays, and hyaluronate sodium 10 grams, dextran 90 grams.
The prescription and the consumption of granule of the present invention and powder spray are: in 100 gram granule and powder sprays, and hyaluronate sodium 20 grams, carboxymethyl cellulose 80 grams.
The prescription and the consumption of granule of the present invention and powder spray are: in 100 gram granule and powder sprays, and hyaluronate sodium 10 grams, chondroitin sulfate 3 grams, all the other are dextrans.
The prescription and the consumption of granule of the present invention and powder spray are: in 100 gram granule and powder sprays, and hyaluronate sodium 10 grams, heparin sodium 0.1 gram (tire and be no less than 150/mg), all the other are dextrans.
The prescription and the consumption of granule of the present invention and powder spray are: in 100 gram granule and powder sprays, and hyaluronate sodium 10 grams, dexamethasone sodium phosphate 0.1 gram, all the other are dextrans
The manufacture method one of granule of the present invention and powder spray: by the prescription and the consumption of granule of the present invention and powder spray, the accurate weighing of each components in certain proportion, after the mixing, coating-dividing sealing promptly gets granule of the present invention and powder spray with oxirane or microwave degerming.
The manufacture method two of granule of the present invention and powder spray: by the prescription and the consumption of granule of the present invention and powder spray, with oxirane or microwave degerming, coating-dividing sealing promptly gets granule of the present invention and powder spray to each composition in proportion more respectively
Owing to contain hyaluronate sodium in granule of the present invention and the powder spray, can act on the adhesion position effectively, be easy to use, do not influence normal wound healing, have biocompatibility and degradability.And granule of the present invention and powder spray hyaluronate sodium molecular weight are big, and retention time is long in the body, and the barrier action during wound tissue's reparation is obvious, so its preventing adhesiving effect is remarkable.Through zoopery and clinic trial, prevention and the posterior synechiae of treatment surgical operation, it is all better than the effect of other medicines and barrier to reduce post-operative complication.
Embodiments of the invention:
1. granule of the present invention and powder spray in 100 grams, are got hyaluronate sodium 100 grams, prepare according to the method for the invention.
2. granule of the present invention and powder spray in 100 grams, are got hyaluronate sodium 10 grams, and dextran 90 grams prepare according to the method for the invention.
3. granule of the present invention and powder spray in 100 grams, are got hyaluronate sodium 20 grams, and carboxymethyl cellulose 80 grams prepare according to the method for the invention.
4. granule of the present invention and powder spray in 100 grams, are got hyaluronate sodium 10 grams, chondroitin sulfate 3 grams, and all the other are dextrans, prepare according to the method for the invention.
5. granule of the present invention and powder spray in 100 grams, are got hyaluronate sodium 10 gram, and (tire is no less than that 150 units/mg), all the other are dextrans to heparin sodium 0.1 gram, prepares according to the method for the invention.
6. granule of the present invention and powder spray in 100 grams, are got hyaluronate sodium 10 grams, dexamethasone sodium phosphate 0.1 gram, and all the other are dextrans, prepare according to the method for the invention
Claims (7)
1. one contains granule and the powder spray that hyaluronate sodium is a main component, is used for prevention and the posterior synechiae of treatment surgical operation.Also can contain other active substance and interleaving agent in its prescription, be used for operation such as abdominal surgery, department of obstetrics and gynecology and cardiothoracic surgery back prevention peritoneal tissues or pericardium adhesion, also can be used for preventing around arthroscopy, the nervous tissue, bone surgery infectious-related complication such as tendon repair.Described active substance such as anticoagulant, antiinflammatory, calcium channel blocker, cytostatic agent, proteolytic enzyme etc.
2. according to described granule of claim 1 and powder spray, it is characterized in that containing hyaluronate sodium in the prescription, both extraction had obtained this hyaluronic acid sodium in animal body, and also bacterial fermentation makes molecular weight 50-500 ten thousand dalton
3. according to described granule of claim 1 and powder spray, its feature also is to add other interleaving agent and pharmacological active substance as required in the prescription.Described interleaving agent such as agar, albumin, Oleum Camphora, carboxymethyl cellulose, chondroitin sulfate, dextran, fat, Radix Acaciae senegalis, olive oil, paraffin, phospholipid, polyvinylpyrrolidone, polysiloxanes, vaseline, gelatin, oxidized regenerated cellulose, expanded polytetrafluoroethylsealing etc.Described active substance such as anticoagulant, antiinflammatory, calcium channel blocker, cytostatic agent and protein hydrolytic reagent, anticoagulant such as dicoumarol, heparin and hirudin etc.; Antihistaminic such as antiinflammatory such as promethazine, amcinonides such as dexamethasone, hydrocortisone, andrographolide, NSAID (non-steroidal anti-inflammatory drug) such as ibuprofen, oxyphenbutazone, tolmetin; Calcium channel blocker example hydrochloric acid diltiazem, nifedipine, verapamil hydrochloride etc.; Cytostatic agent such as fluorouracil; Protein hydrolytic reagent such as hyaluronidase, streptokinase, urokinase, pepsin, trypsin, cytoplastin, plasminogen (tPA) etc.
4. according to described granule of claim 1 and powder spray, its feature is that also the interleaving agent of hyaluronic acid and adding and active component all are mixed in proportion with solid particle or dust cloud form.
5. the prescription and the amount ranges of this serial granule and powder spray is characterized in that the hyaluronic acid sodium content is 1%-100%, and when adding other interleaving agent, its content is 0-99%, and when adding medicine, its consumption meets the pharmacopeia regulation.
6. the manufacture method of this serial granule and powder spray, it is characterized in that: behind each components in certain proportion mixing, coating-dividing sealing is sterilized with oxirane or microwave again
7. the manufacture method of this serial granule and powder spray, its feature also is: each composition is respectively with after oxirane or the microwave sterilizating, again coating-dividing sealing in proportion
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98110311A CN1116044C (en) | 1998-06-24 | 1998-06-24 | Antisticking particle and powder containing sodium hyaluronate and their preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98110311A CN1116044C (en) | 1998-06-24 | 1998-06-24 | Antisticking particle and powder containing sodium hyaluronate and their preparation process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1239657A true CN1239657A (en) | 1999-12-29 |
| CN1116044C CN1116044C (en) | 2003-07-30 |
Family
ID=5220372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98110311A Expired - Fee Related CN1116044C (en) | 1998-06-24 | 1998-06-24 | Antisticking particle and powder containing sodium hyaluronate and their preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1116044C (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100333804C (en) * | 2003-04-18 | 2007-08-29 | 上海建华精细生物制品有限公司 | Sodium hyaluronate anti-adhesion film, and its prepn. method |
| CN100386090C (en) * | 2006-07-08 | 2008-05-07 | 青岛博益特生物材料有限公司 | Medical dust cloud agent or granular agent and its use |
| CN102427808A (en) * | 2009-05-14 | 2012-04-25 | 菲迪雅制药股份公司 | New medicines for topic use based on sulfated hyaluronic acid as activating or inhibiting agent of the cytokine activity |
| CN101287411B (en) * | 2005-04-28 | 2013-03-06 | 普罗秋斯生物医学公司 | Pharma-informatics system |
| CN103948623A (en) * | 2014-05-04 | 2014-07-30 | 青岛市城阳区人民医院 | Anti-adhesion dry powder inhalation for orthopedic surgery and preparation method thereof |
| CN103961710A (en) * | 2014-05-04 | 2014-08-06 | 青岛市城阳区人民医院 | Anti-adhesion dry powder inhalation for orthopedics department postoperative joint tissues, and preparation of anti-adhesion dry powder inhalation |
| CN103961366A (en) * | 2014-05-04 | 2014-08-06 | 青岛市城阳区人民医院 | Anti-adhesion dry powder inhalation for orthopedics department post operation, and preparation of anti-adhesion dry powder inhalation |
| CN103961708A (en) * | 2014-05-04 | 2014-08-06 | 青岛市城阳区人民医院 | Anti-adhesion dry powder inhaler used after orthopedic surgeries and preparing method thereof |
| CN106794140A (en) * | 2014-05-30 | 2017-05-31 | 娜塔莉亚·米克拉维娜·德卡奇 | Pharmaceutical composition based on active material stablizing solution |
| CN110840894A (en) * | 2019-12-19 | 2020-02-28 | 温州医科大学附属第一医院 | Composite scar-resistant silicone spray and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1240316B (en) * | 1990-02-21 | 1993-12-07 | Ricerca Di Schiena Del Dr. Michele G. Di Schiema & C. | COMPOSITIONS BASED ON HIGH MOLECULAR WEIGHT HYLURONIC ACID ADMINISTRABLE BY TOPIC FOR THE TREATMENT OF INFLAMMATIONS OF THE ORAL CABLE, FOR COSMETICS AND HYGIENE OF THE ORAL CABLE |
| IT1243435B (en) * | 1990-10-05 | 1994-06-10 | Altergon Sa | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL USE INCLUDING HYALURONIC ACID SODIUM SALT AND DISINFECTANT SUBSTANCES |
| JP2000502714A (en) * | 1996-01-11 | 2000-03-07 | ハイアル ファーマスティカル コーポレイション | Oral administration of an effective amount of hyaluronic acid type |
-
1998
- 1998-06-24 CN CN98110311A patent/CN1116044C/en not_active Expired - Fee Related
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100333804C (en) * | 2003-04-18 | 2007-08-29 | 上海建华精细生物制品有限公司 | Sodium hyaluronate anti-adhesion film, and its prepn. method |
| CN101287411B (en) * | 2005-04-28 | 2013-03-06 | 普罗秋斯生物医学公司 | Pharma-informatics system |
| CN100386090C (en) * | 2006-07-08 | 2008-05-07 | 青岛博益特生物材料有限公司 | Medical dust cloud agent or granular agent and its use |
| CN102427808A (en) * | 2009-05-14 | 2012-04-25 | 菲迪雅制药股份公司 | New medicines for topic use based on sulfated hyaluronic acid as activating or inhibiting agent of the cytokine activity |
| CN102427808B (en) * | 2009-05-14 | 2020-05-19 | 菲迪亚制药股份公司 | Novel agents for topical application based on sulphated hyaluronic acid as activator or inhibitor of cytokine activity |
| CN103961366A (en) * | 2014-05-04 | 2014-08-06 | 青岛市城阳区人民医院 | Anti-adhesion dry powder inhalation for orthopedics department post operation, and preparation of anti-adhesion dry powder inhalation |
| CN103961710A (en) * | 2014-05-04 | 2014-08-06 | 青岛市城阳区人民医院 | Anti-adhesion dry powder inhalation for orthopedics department postoperative joint tissues, and preparation of anti-adhesion dry powder inhalation |
| CN103961708A (en) * | 2014-05-04 | 2014-08-06 | 青岛市城阳区人民医院 | Anti-adhesion dry powder inhaler used after orthopedic surgeries and preparing method thereof |
| CN103948623B (en) * | 2014-05-04 | 2016-08-31 | 青岛市城阳区人民医院 | A kind of bone surgery anti powder spray and preparation method thereof |
| CN103948623A (en) * | 2014-05-04 | 2014-07-30 | 青岛市城阳区人民医院 | Anti-adhesion dry powder inhalation for orthopedic surgery and preparation method thereof |
| CN106794140A (en) * | 2014-05-30 | 2017-05-31 | 娜塔莉亚·米克拉维娜·德卡奇 | Pharmaceutical composition based on active material stablizing solution |
| CN110840894A (en) * | 2019-12-19 | 2020-02-28 | 温州医科大学附属第一医院 | Composite scar-resistant silicone spray and preparation method thereof |
| CN110840894B (en) * | 2019-12-19 | 2020-06-02 | 温州医科大学附属第一医院 | Composite scar-resistant silicone spray and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1116044C (en) | 2003-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2195039B1 (en) | Surgical hydrogel | |
| CN102399295B (en) | Low-sulfhydrylation-modification-degree biocompatible high-molecular sulfhydrylation derivatives, cross-linking material thereof, and purpose thereof | |
| US6869938B1 (en) | Compositions of polyacids and polyethers and methods for their use in reducing adhesions | |
| CA2377544C (en) | Hyaluronic acid anti-adhesion barrier | |
| EP1624935B1 (en) | Anti-adhesion composites and methods os use thereof | |
| JP2000513258A (en) | Use of oxidized cellulose and its complexes for chronic wound healing | |
| JP2002531532A (en) | Sterilized conjugate of therapeutic peptide combined with polysaccharide | |
| JP2003530136A (en) | Compositions of polyacids and polyethers and their use in reducing adhesion | |
| CN1116044C (en) | Antisticking particle and powder containing sodium hyaluronate and their preparation process | |
| DK175597B1 (en) | Use of a tissue plasminogen activator (t-PA) for the preparation of a composition for use in preventing fibrin deposition or adherence formation or recovery, topical compositions and dispensing devices for. | |
| JPH11506741A (en) | Prevention of postoperative adhesion and use of hydroxyethyl starch as intraluminal carrier device | |
| TW201815427A (en) | Multiphase gel | |
| CN103285030A (en) | Xanthan gum-containing anti-blocking preparation | |
| WO1999003481A1 (en) | Compositions for lubricating and separating tissues and biological membranes | |
| CN109568635B (en) | In-situ expansion high-water-absorption hemostatic material and preparation method thereof | |
| CN1351892A (en) | In vivo self degraded epidural adhesion preventing and composite medicine slow-release biological film | |
| CN1203789A (en) | Medicine for therapeutic and operating purpose and preparing method thereof | |
| CN1203790A (en) | Medicine for curing and operating purpose and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Ling Peixue Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice |
Addressee: Ling Peixue Document name: Notification of Termination of Patent Right |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20030730 Termination date: 20100624 |